Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung

Aktualisierungshinweis

Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.

Publication History

Received: 26 June 2025

Accepted: 15 July 2025

Article published online:
24 December 2025

• Literatur

• 1 Raverdy V, Tavaglione F, Chatelain E. et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 2024; 30: 3624-3633
• 2 Jamialahmadi O, De Vincentis A, Tavaglione F. et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 2024; 30: 3614-3623
• 3 Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol 2025; 13: 134-148
• 4 Stefan N, Targher G. Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine. Nat Rev Gastroenterol Hepatol 2025; 22: 226-227
• 5 Verrastro O, Panunzi S, Castagneto-Gissey L. et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023; 401: 1786-1797
• 6 Younossi ZM, Golabi P, Paik JM. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77: 1335-1347
• 7 Estes C, Anstee QM, Arias-Loste MT. et al. Modeling MASLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 2018; 69: 896-904
• 8 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022; 10: 284-296
• 9 Younossi ZM, Golabi P, Price JK. et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol 2024; 22: 1999
• 10 Njei B, Al-Ajlouni YA, Ugwednum D. et al. Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review. Transl Gastroenterol Hepatol 2023; 9: 11
• 11 Eigentler T, Lomberg D, Machann J. et al. Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. Ann Intern Med 2020; 172: 836-837
• 12 Abeysekera KWM, Valenti L, Younossi Z. et al. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol 2024; 9: 83-91
• 13 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
• 14 Schön M, Prystupa K, Mori T. et al. Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort. Lancet Diabetes Endocrinol 2024; 12: 119-131
• 15 Rinella ME, Lazarus JV, Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966-1986
• 16 Roeb E, Canbay A, Bantel H. et al. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Z Gastroenterol 2022; 60: 1346-1421
• 17 Roeb E, Canbay A, Bantel H. et al. Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion-assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2024; 62: 1077-1087
• 18 European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity; Clinical Practice Guideline Panel. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia 2024; 67: 2375-2392
• 19 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659-689
• 20 Cusi K, Abdelmalek MF, Apovian CM. et al. Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Statement of the American Diabetes Association. Diabetes Care 2025; 48: 1-26
• 21 Tilg H, Moschen AR, Roden M. MASLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42
• 22 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
• 23 Bril F, McPhaul MJ, Caulfield MP. et al. Performance of the SteatoTest, ActiTest, MASHTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019; 67: 303-311
• 24 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1–9
• 25 Kim J, Seki E. Unveiling the cancer risk nexus of the steatotic liver. Trends Endocrinol Metab 2024; 35: 708
• 26 Adams LA, Anstee QM, Tilg H. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
• 27 Aminian A, Al-Kurd A, Wilson R. et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021; 326: 2031-2042
• 28 Sanyal AJ, Newsome PN, Kliers I. et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.; ESSENCE Study Group. N Engl J Med 2025; 392: 2089-2099
• 29 Loomba R, Abdelmalek MF, Armstrong MJ. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8: 511-522
• 30 Loomba R, Hartman ML, Lawitz EJ. et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 2024; 391: 299-310
• 31 Sanyal AJ, Pierre B, Fraessdorf M. et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med 2024; 391: 311-319
• 32 Harrison SA, Bedossa P, Guy CD. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024; 390: 497-509
• 33 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. FDA 14.03.2024, abgerufen am 02.07.2024.
• 34 Francque SM, Bedossa P, Ratziu V. et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in MASH. N Engl J Med 2021; 385: 1547-1558
• 35 Loomba R, Sanyal AJ, Kowdley KV. et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in MASH. N Engl J Med 2023; 389: 998-1008